498 related articles for article (PubMed ID: 23552371)
1. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
Matsuoka K; Koreth J; Kim HT; Bascug G; McDonough S; Kawano Y; Murase K; Cutler C; Ho VT; Alyea EP; Armand P; Blazar BR; Antin JH; Soiffer RJ; Ritz J
Sci Transl Med; 2013 Apr; 5(179):179ra43. PubMed ID: 23552371
[TBL] [Abstract][Full Text] [Related]
2. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Asano T; Meguri Y; Yoshioka T; Kishi Y; Iwamoto M; Nakamura M; Sando Y; Yagita H; Koreth J; Kim HT; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Maeda Y; Tanimoto M; Ritz J; Matsuoka KI
Blood; 2017 Apr; 129(15):2186-2197. PubMed ID: 28151427
[TBL] [Abstract][Full Text] [Related]
3. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.
Meguri Y; Asano T; Yoshioka T; Iwamoto M; Ikegawa S; Sugiura H; Kishi Y; Nakamura M; Sando Y; Kondo T; Sumii Y; Maeda Y; Matsuoka KI
Front Immunol; 2022; 13():891925. PubMed ID: 35983059
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.
Whangbo JS; Kim HT; Nikiforow S; Koreth J; Alho AC; Falahee B; Kim S; Dusenbury K; Fields MJ; Reynolds CG; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J
Blood Adv; 2019 Apr; 3(7):984-994. PubMed ID: 30936059
[TBL] [Abstract][Full Text] [Related]
5. Low-dose IL-2 selectively activates subsets of CD4
Hirakawa M; Matos TR; Liu H; Koreth J; Kim HT; Paul NE; Murase K; Whangbo J; Alho AC; Nikiforow S; Cutler C; Ho VT; Armand P; Alyea EP; Antin JH; Blazar BR; Lacerda JF; Soiffer RJ; Ritz J
JCI Insight; 2016 Nov; 1(18):e89278. PubMed ID: 27812545
[TBL] [Abstract][Full Text] [Related]
6. Low-dose IL-2 expands CD4
Li Y; Liu X; Wang W; Wang S; Zhang J; Jiang S; Wang Y; Li L; Li J; Zhang Y; Huang H
Ren Fail; 2018 Nov; 40(1):280-288. PubMed ID: 29619880
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 and regulatory T cells in graft-versus-host disease.
Koreth J; Matsuoka K; Kim HT; McDonough SM; Bindra B; Alyea EP; Armand P; Cutler C; Ho VT; Treister NS; Bienfang DC; Prasad S; Tzachanis D; Joyce RM; Avigan DE; Antin JH; Ritz J; Soiffer RJ
N Engl J Med; 2011 Dec; 365(22):2055-66. PubMed ID: 22129252
[TBL] [Abstract][Full Text] [Related]
8. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
Matsuoka K; Kim HT; McDonough S; Bascug G; Warshauer B; Koreth J; Cutler C; Ho VT; Alyea EP; Antin JH; Soiffer RJ; Ritz J
J Clin Invest; 2010 May; 120(5):1479-93. PubMed ID: 20389017
[TBL] [Abstract][Full Text] [Related]
9. Comparative dose-responses of recombinant human IL-2 and IL-7 on STAT5 phosphorylation in CD4+FOXP3- cells versus regulatory T cells: a whole blood perspective.
Dupont G; Demaret J; Venet F; Malergue F; Malcus C; Poitevin-Later F; Morel J; Monneret G
Cytokine; 2014 Sep; 69(1):146-9. PubMed ID: 24947990
[TBL] [Abstract][Full Text] [Related]
10. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.
Coenen JJ; Koenen HJ; van Rijssen E; Kasran A; Boon L; Hilbrands LB; Joosten I
Bone Marrow Transplant; 2007 May; 39(9):537-45. PubMed ID: 17351648
[TBL] [Abstract][Full Text] [Related]
13. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells.
Shan J; Feng L; Sun G; Chen P; Zhou Y; Xia M; Li H; Li Y
Immunobiology; 2015 Apr; 220(4):510-7. PubMed ID: 25468562
[TBL] [Abstract][Full Text] [Related]
14. Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease.
Pérol L; Martin GH; Maury S; Cohen JL; Piaggio E
Immunol Lett; 2014 Dec; 162(2 Pt B):173-84. PubMed ID: 25445496
[TBL] [Abstract][Full Text] [Related]
15. Very Low Numbers of CD4
Copsel S; Wolf D; Kale B; Barreras H; Lightbourn CO; Bader CS; Alperstein W; Altman NH; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1788-1794. PubMed ID: 29751114
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells.
Kim N; Jeon YW; Nam YS; Lim JY; Im KI; Lee ES; Cho SG
Cytokine; 2016 Feb; 78():22-6. PubMed ID: 26624506
[TBL] [Abstract][Full Text] [Related]
17. Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.
Matsuoka KI
Int J Hematol; 2018 Feb; 107(2):130-137. PubMed ID: 29234980
[TBL] [Abstract][Full Text] [Related]
18. Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives.
Ikegawa S; Matsuoka KI
Front Immunol; 2021; 12():713358. PubMed ID: 34526990
[TBL] [Abstract][Full Text] [Related]
19. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.
Zorn E; Mohseni M; Kim H; Porcheray F; Lynch A; Bellucci R; Canning C; Alyea EP; Soiffer RJ; Ritz J
Biol Blood Marrow Transplant; 2009 Mar; 15(3):382-8. PubMed ID: 19203731
[TBL] [Abstract][Full Text] [Related]
20. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
